RPP25

Summary

RPP25 (ribonuclease P/MRP subunit p25, HGNC:30361) is a protein-coding gene on chromosome 15q24.2, encoding Ribonuclease P protein subunit p25 (Q9BUL9). Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5’-ends.

Enables ribonuclease P RNA binding activity. Contributes to ribonuclease P activity. Involved in tRNA 5’-leader removal. Located in centriolar satellite and nucleoplasm. Part of multimeric ribonuclease P complex and ribonuclease MRP complex. Biomarker of autistic disorder.

Source: NCBI Gene 54913 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 2 total
• MANE Select transcript: NM_017793

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30361
Approved symbol	RPP25
Name	ribonuclease P/MRP subunit p25
Location	15q24.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20374
Ensembl gene	ENSG00000178718
Ensembl biotype	protein_coding
OMIM	619235
Entrez	54913

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000322177

RefSeq mRNA: 1 — MANE Select: NM_017793 NM_017793

CCDS: CCDS10274

Canonical transcript exons

ENST00000322177 — 1 exons

Exon	Start	End
ENSE00001243292	74954418	74956772

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 95.51.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.5035 / max 113.6586, expressed in 1583 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150944	10.0557	1503
150946	1.1336	690
150945	0.8448	537
150943	0.2108	99
150949	0.1275	48
150948	0.0929	29
150947	0.0381	19

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	95.51	gold quality
parotid gland	UBERON:0001831	94.19	gold quality
lateral nuclear group of thalamus	UBERON:0002736	94.17	gold quality
pons	UBERON:0000988	93.63	gold quality
body of tongue	UBERON:0011876	92.64	gold quality
subthalamic nucleus	UBERON:0001906	92.58	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.50	gold quality
lateral globus pallidus	UBERON:0002476	92.15	gold quality
cardia of stomach	UBERON:0001162	91.76	gold quality
substantia nigra pars compacta	UBERON:0001965	91.48	gold quality
ventral tegmental area	UBERON:0002691	91.47	gold quality
pylorus	UBERON:0001166	91.46	gold quality
heart right ventricle	UBERON:0002080	91.36	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.35	gold quality
inferior vagus X ganglion	UBERON:0005363	91.00	gold quality
pericardium	UBERON:0002407	90.50	gold quality
superior vestibular nucleus	UBERON:0007227	90.19	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	89.76	gold quality
pharyngeal mucosa	UBERON:0000355	89.58	gold quality
mucosa of transverse colon	UBERON:0004991	89.54	gold quality
dorsal plus ventral thalamus	UBERON:0001897	89.28	gold quality
tongue	UBERON:0001723	89.02	gold quality
saphenous vein	UBERON:0007318	88.94	gold quality
superior surface of tongue	UBERON:0007371	87.92	gold quality
dorsal root ganglion	UBERON:0000044	87.63	gold quality
nipple	UBERON:0002030	87.14	gold quality
biceps brachii	UBERON:0001507	87.10	gold quality
renal medulla	UBERON:0000362	86.78	gold quality
trigeminal ganglion	UBERON:0001675	86.73	gold quality
medulla oblongata	UBERON:0001896	86.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

44 targeting RPP25, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-876-3P	98.76	68.23	945
HSA-MIR-4483	98.09	64.12	1642

Literature-anchored findings (GeneRIF, showing 6)

• analyses of interactions with deletion mutant proteins indicate that the Alba-type core domain of both Rpp20 and Rpp25 contains most of the determinants for mutual association and P3 RNA recognition. (PMID:20215441)
• Taken together, these findings suggest a potential role for the RPP25 gene transcript in the neurobiology of developmental brain disorders. (PMID:20632321)
• Rpp25 is a major target of autoantibodies to the Th/To autoantigen complex (PMID:23587095)
• Study showed the crystal structure of Rpp20/Rpp25 complex, and confirmed that Rpp20 and Rpp25 exhibit similar molecular structures to one another, to their yeast homologs (Pop7 andPop6, respectively), and to archaeal Alba proteins. These proteins do not seem to undergo significant conformational change upon RNA binding, suggesting that they interact with their cognate RNAs via a pre-formed binding surface. (PMID:29625199)
• LINC00319 promotes migration, invasion and epithelial-mesenchymal transition process in cervical cancer by regulating miR-3127-5p/RPP25 axis. (PMID:31942724)
• Crystal structure of human RPP20-RPP25 proteins in complex with the P3 domain of lncRNA RMRP. (PMID:33571640)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	rpp25a	ENSDARG00000101536
danio_rerio	rpp25b	ENSDARG00000112256
mus_musculus	Rpp25	ENSMUSG00000062309
rattus_norvegicus	Rpp25	ENSRNOG00000018812
drosophila_melanogaster	Rpp25	FBGN0033092
caenorhabditis_elegans		WBGENE00014020

Paralogs (1): RPP25L (ENSG00000164967)

Protein

Protein identifiers

Ribonuclease P protein subunit p25 — Q9BUL9 (reviewed: Q9BUL9)

All UniProt accessions (1): Q9BUL9

UniProt curated annotations — full annotation on UniProt →

Function. Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5’-ends. Also a component of the MRP ribonuclease complex, which cleaves pre-rRNA sequences.

Subunit / interactions. Component of nuclear RNase P and RNase MRP ribonucleoproteins. RNase P consists of a catalytic RNA moiety and 10 different protein chains; POP1, POP4, POP5, POP7, RPP14, RPP21, RPP25, RPP30, RPP38 and RPP40. Within the RNase P complex, POP1, POP7 and RPP25 form the ‘finger’ subcomplex, POP5, RPP14, RPP40 and homodimeric RPP30 form the ‘palm’ subcomplex, and RPP21, POP4 and RPP38 form the ‘wrist’ subcomplex. All subunits of the RNase P complex interact with the catalytic RNA. Several subunits of RNase P are also part of the RNase MRP complex. RNase MRP consists of a catalytic RNA moiety and about 8 protein subunits; POP1, POP7, RPP25, RPP30, RPP38, RPP40 and possibly also POP4 and POP5. POP7 forms a heterodimer with RPP25 that binds to the P3 stem loop of the catalytic RNA.

Subcellular location. Nucleus. Nucleolus.

Similarity. Belongs to the histone-like Alba family.

RefSeq proteins (1): NP_060263* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002775	DNA/RNA-bd_Alba-like	Domain
IPR036882	Alba-like_dom_sf	Homologous_superfamily
IPR051958	Alba-like_NAB	Family

Pfam: PF01918

Enzyme classification (BRENDA):

• EC 3.1.26.5 — ribonuclease P (BRENDA: 188 organisms, 407 substrates, 80 inhibitors, 54 Km, 43 kcat entries)

Substrate kinetics (BRENDA)

24 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
HUMAN PRE-TRNATYR	0.0001–0.0005	5
PRE-TRNATYR	—	5
PRE-TRNAASP	—	4
PTRNATYR	0.0002–0.0305	4
TRNA PRECURSOR	—	4
PRE-TRNA-TYR	0.0001	2
PRE-TRNATHR(AGT)	0.0035–0.05	2
RNASE P RIBOSWITCH A	0.0064–0.0081	2
TRNAPHE (G+1) PRECURSOR	—	2
TRNATYR	—	2
PMINI3PBUG	0.0013	1
PRE-TRNA	—	1
PRE-TRNA SUPS1 TRNASER	0.0002	1
PRE-TRNA-ASP	0.0003	1
PRE-TRNA-CYS	0.0006	1

UniProt features (18 total): strand 6, helix 3, region of interest 2, compositionally biased region 2, modified residue 2, chain 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
6CWX	X-RAY DIFFRACTION	2.25
6LT7	X-RAY DIFFRACTION	2.7
9UH7	ELECTRON MICROSCOPY	2.84
9UH9	ELECTRON MICROSCOPY	3.47
6AHU	ELECTRON MICROSCOPY	3.66
6AHR	ELECTRON MICROSCOPY	3.92
9UHA	ELECTRON MICROSCOPY	3.93

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUL9-F1	80.46	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 172, 182

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-6784531	tRNA processing in the nucleus
R-HSA-6791226	Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-72306	tRNA processing
R-HSA-72312	rRNA processing
R-HSA-8868773	rRNA processing in the nucleus and cytosol
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 125 (showing top): ELVIDGE_HYPOXIA_DN, GOBP_RIBOSOME_BIOGENESIS, GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, PEREZ_TP63_TARGETS, GOBP_TRNA_METABOLIC_PROCESS, ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN, CHX10_01, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, GOMF_RNA_ENDONUCLEASE_ACTIVITY, HAMAI_APOPTOSIS_VIA_TRAIL_DN, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, HOXA4_Q2, GOBP_TRNA_PROCESSING

GO Biological Process (3): tRNA 5’-leader removal (GO:0001682), rRNA processing (GO:0006364), tRNA processing (GO:0008033)

GO Molecular Function (5): RNA binding (GO:0003723), ribonuclease P RNA binding (GO:0033204), nucleic acid binding (GO:0003676), ribonuclease P activity (GO:0004526), protein binding (GO:0005515)

GO Cellular Component (6): ribonuclease MRP complex (GO:0000172), nucleoplasm (GO:0005654), nucleolus (GO:0005730), multimeric ribonuclease P complex (GO:0030681), centriolar satellite (GO:0034451), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Metabolism of RNA	2
tRNA processing	1
rRNA processing in the nucleus and cytosol	1
rRNA processing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
binding	2
nuclear lumen	2
cellular anatomical structure	2
tRNA 5’-end processing	1
rRNA metabolic process	1
ribosome biogenesis	1
tRNA metabolic process	1
nucleic acid binding	1
RNA binding	1
tRNA-specific ribonuclease activity	1
RNA endonuclease activity producing 5’-phosphomonoesters, hydrolytic mechanism	1
sno(s)RNA-containing ribonucleoprotein complex	1
endoribonuclease complex	1
intracellular membraneless organelle	1
ribonuclease P complex	1
centrosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

628 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RPP25	RPP38	P78345	998
RPP25	RPP30	P78346	998
RPP25	RPP40	O75818	995
RPP25	POP4	O95707	995
RPP25	POP5	Q969H6	978
RPP25	POP7	O75817	773
RPP25	SCAMP5	Q8TAC9	672
RPP25	POP1	Q99575	638
RPP25	QNG1	Q5T6V5	493
RPP25	MARVELD1	Q9BSK0	472
RPP25	FAM50A	Q14320	431
RPP25	FAM50B	Q9Y247	425
RPP25	ZC3HAV1L	Q96H79	411
RPP25	RPP21	Q9H633	411
RPP25	RPS2	P15880	402

IntAct

124 interactions, top by confidence:

A	B	Type	Score
POP7	RPP25	psi-mi:“MI:0915”(physical association)	0.810
RPP25	POP7	psi-mi:“MI:0914”(association)	0.810
RPP30	POP7	psi-mi:“MI:0914”(association)	0.730
POP1	RPP25	psi-mi:“MI:0915”(physical association)	0.670
POP4	RPP25	psi-mi:“MI:0915”(physical association)	0.670
RPP25	POP4	psi-mi:“MI:0915”(physical association)	0.670
RPP25	POP5	psi-mi:“MI:0915”(physical association)	0.670
RPP25	RPP14	psi-mi:“MI:0915”(physical association)	0.670
C18orf21	POP7	psi-mi:“MI:0914”(association)	0.640
POP4	POP7	psi-mi:“MI:0914”(association)	0.640
NPM1	NVL	psi-mi:“MI:0914”(association)	0.610
SAT1	RPP25	psi-mi:“MI:0915”(physical association)	0.560
	RPP25	psi-mi:“MI:0915”(physical association)	0.560
BANP	RPP25	psi-mi:“MI:0915”(physical association)	0.560
LDOC1	RPP25	psi-mi:“MI:0915”(physical association)	0.560
PNMA1	RPP25	psi-mi:“MI:0915”(physical association)	0.560
KRT15	RPP25	psi-mi:“MI:0915”(physical association)	0.560
SF3B4	RPP25	psi-mi:“MI:0915”(physical association)	0.560
RPP25	PICK1	psi-mi:“MI:0915”(physical association)	0.560
RPP25	BACH2	psi-mi:“MI:0915”(physical association)	0.560
LRRC73	RPP25	psi-mi:“MI:0915”(physical association)	0.560
DDI1	RPP25	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	RPP25	psi-mi:“MI:0915”(physical association)	0.560
RPP25	ABI2	psi-mi:“MI:0915”(physical association)	0.560
ZNF438	RPP25	psi-mi:“MI:0915”(physical association)	0.560
RPP25	PDLIM7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (110): RPP25 (Affinity Capture-MS), RPP25 (Affinity Capture-MS), RPP25 (Affinity Capture-MS), POP1 (Affinity Capture-MS), C3orf17 (Affinity Capture-MS), RPP40 (Affinity Capture-MS), POP5 (Affinity Capture-MS), RABL2A (Affinity Capture-MS), RPP38 (Affinity Capture-MS), RPP30 (Affinity Capture-MS), USP13 (Affinity Capture-MS), RPP14 (Affinity Capture-MS), C18orf21 (Affinity Capture-MS), POP7 (Affinity Capture-MS), RPP25 (Affinity Capture-MS)

ESM2 similar proteins: A6H687, A6NKF1, D3ZBP4, D3ZU57, E2RDP2, F1MH07, P0C0K6, P0DPD7, P0DPE1, P11086, Q002B5, Q08DM2, Q28F19, Q2KIR4, Q3V3V9, Q4KM32, Q4VYA0, Q568Y2, Q58CQ5, Q5E9Y5, Q5JR98, Q5JZY3, Q5PPN2, Q5RE82, Q66H85, Q684M2, Q68FW7, Q6F5E8, Q6P9Q4, Q86TL0, Q8BMZ5, Q8BYG9, Q8CDY7, Q8N5L8, Q8N8Q3, Q8TDZ2, Q8TE68, Q8VDP3, Q8WUJ1, Q91WE3

Diamond homologs: Q2KIR4, Q5PPN2, Q8IAX8, Q8N5L8, Q91WE3, Q99JH1, Q9BUL9, Q8IDN4

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
RPP25	“form complex”	“Ribonuclease MRP complex”	binding
RPP25	“form complex”	“Nucleolar ribonuclease P complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 60 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
tRNA processing	6	51.0×	2e-07
tRNA processing in the nucleus	9	42.2×	1e-10
rRNA processing in the nucleus and cytosol	6	23.0×	2e-05
rRNA processing	6	20.9×	2e-05
Metabolism of RNA	9	8.9×	2e-05
Major pathway of rRNA processing in the nucleolus and cytosol	6	8.8×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
rRNA processing	8	20.2×	1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

10 predictions. Top by Δscore:

Variant	Effect	Δscore
15:74956661:T:C	acceptor_gain	0.4600
15:74956660:CT:C	acceptor_gain	0.4200
15:74956661:TT:T	acceptor_gain	0.4200
15:74956659:CCT:C	acceptor_gain	0.3400
15:74956661:T:TC	acceptor_gain	0.3300
15:74956672:A:T	acceptor_gain	0.2700
15:74956162:T:TG	acceptor_gain	0.2600
15:74956657:CGCCT:C	acceptor_gain	0.2400
15:74955401:A:T	acceptor_gain	0.2200
15:74955898:C:CT	acceptor_gain	0.2000

AlphaMissense

1263 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:74956384:A:G	F67S	0.999
15:74956329:C:A	K85N	0.998
15:74956329:C:G	K85N	0.998
15:74956351:A:T	V78D	0.998
15:74956356:T:A	K76N	0.998
15:74956356:T:G	K76N	0.998
15:74956426:G:T	A53D	0.997
15:74956336:A:G	I83T	0.996
15:74956174:A:G	I137T	0.995
15:74956344:G:C	C80W	0.995
15:74956357:T:A	K76I	0.995
15:74956358:T:C	K76E	0.995
15:74956390:A:T	I65N	0.995
15:74956447:A:G	I46T	0.995
15:74956174:A:T	I137N	0.994
15:74956331:T:C	K85E	0.993
15:74956339:T:A	E82V	0.993
15:74956345:C:T	C80Y	0.993
15:74956346:A:G	C80R	0.993
15:74956452:G:C	S44R	0.993
15:74956452:G:T	S44R	0.993
15:74956454:T:G	S44R	0.993
15:74956465:A:T	V40D	0.993
15:74956348:G:T	T79K	0.992
15:74956378:C:T	G69D	0.992
15:74956384:A:C	F67C	0.992
15:74956449:C:A	K45N	0.992
15:74956449:C:G	K45N	0.992
15:74956266:C:A	W106C	0.991
15:74956266:C:G	W106C	0.991

dbSNP variants (sampled 300 via entrez): RS1000060058 (15:74954080 C>G), RS1000079190 (15:74958314 C>T), RS1000193348 (15:74958036 T>C), RS1001254326 (15:74957886 A>G), RS1001362948 (15:74955224 G>A), RS1001769015 (15:74957608 C>A,G), RS1003035925 (15:74956736 G>A), RS1003254880 (15:74955803 C>A), RS1003329260 (15:74958077 T>C), RS1003330958 (15:74956865 G>A), RS1003777126 (15:74955370 G>A), RS1003932292 (15:74954044 C>T), RS1004523768 (15:74957535 C>A,G,T), RS1005878794 (15:74957016 G>A), RS1006195929 (15:74956729 G>A,C)

Disease associations

OMIM: gene MIM:619235 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006166_88	Diastolic blood pressure x alcohol consumption interaction (2df test)	3.000000e-19
GCST006434_67	Systolic blood pressure x alcohol consumption interaction (2df test)	2.000000e-12
GCST011365_4	Myocardial infarction	4.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004329	alcohol drinking
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
sodium arsenite	affects expression, affects methylation, increases expression	3
entinostat	increases expression, affects cotreatment	2
Panobinostat	increases expression, affects cotreatment	2
Acetaminophen	decreases expression, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
afimoxifene	increases expression, decreases reaction	1
potassium chromate(VI)	affects cotreatment, increases expression	1
ferrous chloride	decreases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
tebuconazole	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
ICG 001	decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
jinfukang	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	decreases expression	1
Arsenic	affects expression	1
Cytarabine	decreases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Estrogens	increases expression, decreases reaction	1
Ribonucleotides	affects binding	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.